PhoreMost in drug target discovery collaboration with Roche 13-Sep-2022 By Jane Byrne UK-based biopharmaceutical company, PhoreMost, is to deploy its in-house expertise and next-generation phenotypic screening platform, SITESEEKER, toward disease-relevant pathways nominated by Roche.
Ligand inks $438m Pfenex buyout to add protein expression tech to portfolio 13-Aug-2020 By Nick Taylor Ligand Pharmaceuticals strikes deal to buy Pfenex for $438 million upfront in cash to gain control of protein expression technology.
